SerbinCommunications

(805) 963-0439 | Toll-Free (800) 876-6425

www.serbin.com LA / NY / UK

Alexander & Turner Inc. Studio

Shannon Associates

Tivantinib™ Mode of Action in nsNSCLC 

Prev Next
Previous

Cyclooxygenases and NSAIDS

medical illustration of Tivantinib™ is designed to block the activity of c-MET, a molecule that plays multiple key roles in human cancer including cancer cell growth,survival, angiogenesis, invasion and metastasis in nsNSCLC (non squamous Non-Small Cell Lung Cancer).
Next medical illustration of Radiation Therapy (SBRT) has yielded promising results for patients who were mostly medically inoperable. The good results have led some institutions to treat medically operable patients with SBRT. Limited Edition Print for Varian Surgical Sciences, exhibit panel, print and event collateral.

RapidArc® Lung Cancer Treatment

Tivantinib™ is designed to block the activity of c-MET, a molecule that plays multiple key roles in human cancer including cancer cell growth,survival, angiogenesis, invasion and metastasis in nsNSCLC (non squamous Non-Small Cell Lung Cancer).

Keywords: Airbrush, Color, 3D, Advertising / Marketing, Biotechnology, Disease Management, Pharmacology, Oncology, Mechanism of Action (MOA)

© Cynthia Turner